RPS will operate as PRA’s strategic solutions division and will be led by PRA’s chief executive officer Colin Shannon. Former RPS chief executive officer Harris Koffer and president Samir Shah have been named president and chief operating officer of the strategic solutions division, respectively.
Since 2000, PRA has performed approximately 2,000 clinical trials in over 80 countries for over 300 clients. RPS is known throughout the industry as the creator of the embedded clinical development model, with an established presence in North America and EMEA, and specialized capabilities in Latin America and Asia. RPS has more than 4,000 employees in over 64 countries. As a result of the merger, PRA now has nearly 10,000 employees with operations and resources in 80 countries across North and South America, Europe, Africa and Asia Pacific.